Innovent Biologics and LG Chem Life Sciences have signed an agreement for tigulixostat, a novel non-purine xanthine oxidase inhibitor (XOI) for the chronic treatment of hyperuricemia in patients with gout.
Under the terms of the strategic partnership and license agreement, Innovent will receive exclusive rights to develop and commercialize the treatment in China.
For the China rights, LG Chem will receive a total of $95.5 million, including a $10 million upfront payment, milestones, and royalties on net product sales in the country.
Tigulixostat was shown to lower serum uric acid (sUA) at all dose levels in a US phase II clinical trial (CLUE Study).
In addition, treatment achieved sUA<5mg/dL as the primary treatment endpoint at 3 months in all dose groups versus placebo and febuxostat.
In the fourth quarter of this year, LG Chem initiated global Phase III clinical trials of Tigulixostat in multiple regions.
Dr. Jeewoong Son, president of LG Chem Life Sciences, said: “Tigulixostat will provide a better treatment option for gout patients in the near future, and our collaboration with Innovent will accelerate the global development of Tigulixostat for patients with high unmet medical needs.
“We are very pleased to enter into this strategic partnership, which is an important milestone for LG Chem as we build global biotech and research capabilities, and look forward to furthering Tigulixostat’s potential through this partnership.
“We look forward to working with Innovent to accelerate the development of Tigulixostat and bring the new XOI drug to market, building on the strong and extensive experience and expertise of both companies.”
Tigulixostat is being developed as a first-line treatment in the United States.